Treg Therapeutics, a biotech developing therapies designed to restore immune tolerance, has announced a partnership with Eva Garland Consulting (EGC) to strengthen its non-dilutive funding strategy. The company is advancing its autoimmune tolerance platform and development programs, aiming for therapies that can restore immune tolerance rather than simply suppress the immune system.
“For an emerging biotech company, capital strategy matters enormously,” TregTherapeutics said in announcing the partnership. “Every dollar needs to move the science forward while preserving as much long-term value for shareholders as possible.”
Funding Science Without Diluting Value
Non-dilutive funding is a central part of TregTherapeutics’ capital strategy. Government grants and other non-dilutive sources can fund meaningful scientific and development work without issuing additional equity. Used alongside private investment, the company says, this funding can help accelerate key programs while allowing investor capital to be deployed where it has the greatest impact.
A Partner That Starts With the Science
TregTherapeutics chose EGC for its deep experience helping life sciences companies identify, pursue, and secure non-dilutive funding opportunities. The company noted that EGC understands a successful funding strategy begins with the science, the development plan, and the milestones that create value.
TregTherapeutics’ goal is to move autoimmune treatment beyond broad immune suppression toward restoring the body’s natural tolerance. “Building something that ambitious requires great science, disciplined capital allocation and the right partners,” the company said. “We’re very pleased to have EGC on the team.”
About TregTherapeutics
TregTherapeutics is an emerging biotechnology company developing an autoimmune tolerance platform, with the goal of creating therapies that restore immune tolerance rather than simply suppress the immune system.
About Eva Garland Consulting
Eva Garland Consulting (EGC) helps life sciences companies identify, pursue, and secure non-dilutive funding opportunities, including government grants, building funding strategies grounded in each company’s science, development plan, and value-creating milestones.
